COVID-19 and immunomodulation treatment for women with reproductive failures
© 2020 Elsevier B.V. COVID-19 pandemic is affecting various areas of health care, including human reproduction. Many women with reproductive failures, during the peri-implantation period and pregnancy, are on the immunotherapy using immune modulators and immunosuppressant due to underlying autoimmune diseases, cellular immune dysfunction, and rheumatic conditions. Many questions have been raised for women with immunotherapy during the COVID-19 pandemic, including infection susceptibility, how to manage women with an increased risk of and active COVID-19 infection. SARS-CoV-2 is a novel virus, and not enough information exists. Yet, we aim to review the data from previous coronavirus outbreaks and current COVID-19 and provide interim guidelines for immunotherapy in women with reproductive failures.
Kwak-Kim, Joanne; Ota, Kuniaki; Sung, Nayoung; Huang, Changsheng; Alsubki, Lujain; Lee, Sungki; Han, Jae Won; Han, Aera; Yang, Xiuhua; Saab, Wael; Derbala, Youssef; Wang, Wen Juan; He, Qiaohua; Liao, Aihua; Takahashi, Toshifumi; Cavalcante, Marcelo Borges; Barini, Ricardo; Bao, Shihua; Fukui, Atsushi; Lédée, Nathalie; and Coulam, Carolyn, "COVID-19 and immunomodulation treatment for women with reproductive failures" (2020). Articles. 82.